Gufic Biosciences Limited

NSEI:GUFICBIO Stock Report

Market Cap: ₹43.3b

Gufic Biosciences Past Earnings Performance

Past criteria checks 2/6

Gufic Biosciences has been growing earnings at an average annual rate of 23.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 16.6% per year. Gufic Biosciences's return on equity is 14.8%, and it has net margins of 10.6%.

Key information

23.5%

Earnings growth rate

20.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate16.6%
Return on equity14.8%
Net Margin10.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Jun 06
We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Recent updates

There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump

Nov 07
There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Jun 06
We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Jun 17
Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

May 07
Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Dec 07
Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Sep 15
This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Aug 12
Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Jun 11
Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

Mar 19
If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Mar 01
What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet

Feb 11
Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet

Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?

Jan 23
Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?

Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company

Jan 05
Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Dec 18
Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Dec 01
Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet

Nov 13
Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet

The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?

Oct 19
The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?

Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?

Sep 14
Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?

I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut

Aug 24
I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut

Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects

Aug 03
Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects

Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)

Jul 09
Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)

Revenue & Expenses Breakdown

How Gufic Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:GUFICBIO Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248,0388491,2060
30 Jun 248,1458641,1530
31 Mar 248,0678611,1320
31 Dec 237,8478421,0920
30 Sep 237,6048231,0260
30 Jun 237,2047939600
31 Mar 236,9067979400
31 Dec 226,7988199220
30 Sep 226,7448268960
30 Jun 226,9378578960
31 Mar 227,7929589130
31 Dec 217,4898848650
30 Sep 217,4348298530
30 Jun 216,7777697820
31 Mar 214,8774426910
31 Dec 204,0053055880
30 Sep 203,5382435570
30 Jun 203,1951234990
31 Mar 203,7882276370
31 Dec 193,6812435780
30 Sep 193,5802325740
30 Jun 193,6402494790
31 Mar 193,5082195250
31 Dec 183,3341645270
30 Sep 183,3531685200
30 Jun 183,1921646110
31 Mar 183,0561654790
31 Dec 172,8871814920
30 Sep 172,6511544550
30 Jun 172,5441244320
31 Mar 172,455904270
31 Dec 162,4191054020
30 Sep 162,329983790
30 Jun 162,201883450
31 Mar 162,022733320
31 Dec 151,806625350
30 Sep 151,588454970
30 Jun 151,500362310
31 Mar 151,516422120
31 Dec 141,533433850
30 Sep 141,503473820
30 Jun 141,366471420
31 Mar 141,230433390
31 Dec 131,104373350

Quality Earnings: GUFICBIO has high quality earnings.

Growing Profit Margin: GUFICBIO's current net profit margins (10.6%) are lower than last year (10.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GUFICBIO's earnings have grown significantly by 23.5% per year over the past 5 years.

Accelerating Growth: GUFICBIO's earnings growth over the past year (3.2%) is below its 5-year average (23.5% per year).

Earnings vs Industry: GUFICBIO earnings growth over the past year (3.2%) did not outperform the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: GUFICBIO's Return on Equity (14.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gufic Biosciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research
Naveed MD.FirstCall Research